Cancer Treatment

Product Details:

• Each tablet contains Tofacitinib 5 mg, a potent Janus kinase (JAK) inhibitor.

• Indications

  Tofamark is indicated for adults in the management of:

   

  • Moderate to severe rheumatoid arthritis

  • Psoriatic arthritis

  • Ulcerative colitis

  • Ankylosing spondylitis

  • Mode of Action

    It works by selectively inhibiting JAK enzymes, reducing pro‑inflammatory cytokine activity, thus alleviating pain, swelling, and preventing joint and tissue damage.

    Dosage & Administration

    • Adults: Typically 5 mg twice daily (or once daily extended-release) depending on the condition and combination therapy.

    • Administration: Can be taken with or without food. Swallow whole. Maintain consistent dosing schedule.

    • Key Benefits

       

      • Reduces inflammation, tenderness, and joint stiffness

      • Improves physical function and quality of life

      • Slows disease progression and structural damage

      • Side Effects & Precautions

         

        Common: headache, upper respiratory infection, diarrhea, nasopharyngitis
        Serious (seek immediate care): blood clots, GI perforation, opportunistic infections (e.g., TB, fungal, herpes zoster)

      • Important Safety Notes:

         

        • Screen for TB, hepatitis B/C, and latent infections before starting

        • Avoid in active infections

        • Regular lab monitoring (CBC, liver, kidney, lipids) advised

        • Not recommended during pregnancy or breastfeeding unless benefits justify risks

        • Packaging & Storage

           

          • Format: 5 mg tablets, pack sizes vary (e.g., 1 × 10 strips or 60‑tablet bottles)

          • Storage: Below 30 °C, protect from moisture and sunlight

          • Target Audience

            • Rheumatologists, gastroenterologists, and specialty clinics

            • Patients with inadequate response or intolerance to conventional DMARDs or biologics

            Manufacturer / Supplier Details

             

            • Available through Aprazer (manufacturer of Tofamark) and Cipla (Tofajak)

            • Export-ready: MOQ 1 box, competitive pricing (₹2,200–₹2,500 per box)

            • ✅ Why List Tofamark 5 mg on IndiaMART?

              • Clinically proven JAK‑inhibitor trusted in autoimmune and inflammatory disorders

              • Attractive margins: cost-effective generics vs. branded options

              • Global demand: key markets across India, Middle East, Africa, Europe.

Product Details:

:

Palbociclib is a targeted anticancer medication, specifically a selective and reversible inhibitor of cyclin-dependent kinases CDK4 and CDK6. It is prescribed for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer, administered orally in 125 mg dosage.

By inhibiting CDK4/6, Palbociclib blocks cancer cell progression from the G1 into the S phase of the cell cycle, effectively halting cell division. When combined with hormonal therapies (e.g., aromatase inhibitors or fulvestrant), it enhances tumor growth control.

• Approved by FDA (2015) and EMA (2016) for combination therapy in HR+/HER2– metastatic or locally advanced breast cancer  

• Used:

   

  • Upfront combination with aromatase inhibitors (letrozole, anastrozole, exemestane)

  • Post-endocrine progression with fulvestrant  

  • Dosage & Administration

     

    Parameter

    Details

    125 mg dose form

    Tablets (also available in 100 mg & 75 mg) Regimen 21 consecutive days on, 7 days off — repeated in 28‑day cycles Administer orally with or without food, at consistent times; swallow whole   Hepatic/Renal No dose change for mild/moderate impairment. For Child‑Pugh C liver cases, reduce to 75 mg Monitoring CBC before each cycle, mid‑cycle (Day 15 of Cycles 1 & 2), with ongoing clinical checks      Clinical Benefits PALOMA‑2 trial: 125 mg Palbociclib + letrozole improved progression-free survival to ~24.8 months vs 14.5 months.   PALOMA‑3 trial: significant PFS improvement and enhanced response rates with Palbociclib + fulvestrant

    .
  • Safety & Side Effects

    • Common: neutropenia (> grade 3), leukopenia, anemia, fatigue, nausea, diarrhea, infections